Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S, S)-[18F]FMeNER-D2: A human whole-body PET study(220 views visite) Takano A, Halldin C, Varrone A, Karlsson P, Sjoholm N, Stubbs JB, Schou M, Airaksinen AJ, Tauscher J, Gulyas B
Keywords Parole chiave: S)-[18f]fmener-D 2, Dosimetry, Norepinephrine Transporter, Noradrenalin Transporter, Radioligand, Radiopharmaceutical Agent, Adult, Analytic Method, Article, Bladder, Brain, Computer Program, Controlled Study, Human, Liver, Lung, Normal Human, Radiation Absorption, Radiation Dose, Radioisotope Distribution, Whole Body Pet, Body Burden, Metabolic Clearance Rate, Morpholines, Norepinephrine Plasma Membrane Transport Proteins, Organ Specificity, Positron-Emission Tomography, Radiation Dosage, Radiometry, Relative Biological Effectiveness, Tissue Distribution, Whole Body Imaging, S) - [18f] Fmener-D 2,
Affiliations Affiliazioni: *** IBB - CNR ***
Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm 171 76, Sweden Radiation Dosimetry Systems, Inc., Palo Alto, CA, United States Lilly Research Laboratories, Indianapolis, IN, United States
References Riferimenti: Blakely, R.D., De Felice, L.J., Hartzell, H.C., Molecular physiology of norepinephrine and serotonin transporters (1994) J Exp Biol, 196, pp. 263-28
Galli, A., Defelice, L.J., Duke, B.J., Moore, K.R., Blakely, R.D., Sodium-dependent norepinephrine-induced currents in norepinephrine- transporter-transfected HEK-293 cells blocked by cocaine and antidepressants (1995) J Exp Biol, 198, pp. 2197-2212
Biederman, J., Spencer, T., Attention-deficit/hyperactivity disorder (ADHD) as a norepinephrine disorder (1999) Biol Psychiatry, 46, pp. 1234-1242
Roy, A., Pickar, D., De Jong, J., Karoum, F., Linnoila, M., Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression (1988) Arch Gen Psychiatry, 45, pp. 849-857
Berzewski, H., Van Moffaert, M., Gagiano, C.A., Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes (1997) Eur Neuropsychopharmacol, 7, pp. 37-S47. , Suppl 1
Massana, J., Reboxetine versus fluoxetine: An overview of efficacy and tolerability (1998) J Clin Psychiatry, 59, pp. 8-10. , Suppl 14
Spencer, T., Biederman, J., Wilens, T., Prince, J., Hatch, M., Jones, J., Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder (1998) Am J Psychiatry, 155, pp. 693-695
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F.R., Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study (2001) Pediatrics, 108, p. 83
Bymaster, F.P., Katner, J.S., Nelson, D.L., Hemrick-Luecke, S.K., Threlkeld, P.G., Heiligenstein, J.H., Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder (2002) Neuropsychopharmacology, 27, pp. 699-711
Schou, M., Halldin, C., Sovago, J., Pike, V.W., Gulyas, B., Mozley, P.D., Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER (2003) Nucl Med Biol, 30, pp. 707-714
Seneca, N., Gulyas, B., Varrone, A., Schou, M., Airaksinen, A., Tauscher, J., Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: A PET study in nonhuman primate brain using (S,S)-[18F] FMeNER-D2 (2006) Sychopharmacology (Berl), 188, pp. 119-127
Seneca, N., Andree, B., Sjoholm, N., Schou, M., Pauli, S., Mozley, P.D., Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates (2005) Nucl Med Commun, 26, pp. 695-700
Wrobel, M.C., Carey, J.E., Sherman, P.S., Kilbourn, M.R., Simplifying the dosimetry of carbon-11-labeled radiopharmaceuticals (1997) J Nucl Med, 38, pp. 654-660
Cristy, M., Eckerman, K.F., (1987) Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources. I. Methods, , ORNL/TM-8381/V1 (Oak Ridge National Laboratory), April
Cloutier, R.J., Smith, S.A., Watson, E.E., Snyder, W.S., Warner, G.G., Dose to the fetus from radionuclides in the bladder (1973) Health Phys, 25, pp. 147-161
Stabin, M.G., Siegel, J.A., Physical models and dose factors for use in internal dose assessment (2003) Health Phys, 85, pp. 294-310
Stabin, M.G., Sparks, R.B., Crowe, E., OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine (2005) J Nucl Med, 46, pp. 1023-1027
Fowler, J.S., Ding, Y.S., Logan, J., MacGregor, R.R., Shea, C., Garza, V., Species differences in [11C]clorgyline binding in brain (2001) Nucl Med Biol, 28, pp. 779-785
Lu, J.Q., Ichise, M., Liow, J.S., Ghose, S., Vines, D., Innis, R.B., Biodistribution and radiation dosimetry of the serotonin transporter ligand 11C-DASB determined from human whole-body PET (2004) J Nucl Med, 45, pp. 1555-1559
Tipre, D.N., Lu, J.Q., Fujita, M., Ichise, M., Vines, D., Innis, R.B., Radiation dosimetry estimates for the PET serotonin transporter probe 11C-DASB determined from whole-body imaging in non-human primates (2004) Nucl Med Commun, 25, pp. 81-86
Stabin, M.G., MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine (1996) J Nucl Med, 37, pp. 538-546
Takano, A., Suhara, T., Sudo, Y., Inoue, M., Hashimoto, K., Comparative evaluation of two serotonin transporter ligands in the human brain: [11C](+)McN5652 and [11C]cyanoimipramine (2002) Eur J Nucl Med Mol Imaging, 29, pp. 1289-1297
Ding, Y.S., Lin, K.S., Garza, V., Carter, P., Alexoff, D., Logan, J., Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs (2003) Synapse, 50, pp. 345-352
Mejia, A.A., Nakamura, T., Masatoshi, I., Hatazawa, J., Masaki, M., Watanuki, S., Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies (1991) J Nucl Med, 32, pp. 699-706
Radiation dose to patients from radiopharmaceutical (1998) Ann ICRP, p. 28. , International Commission on Radiological Protection. ICRP Publication 80
Robeson, W., Dhawan, V., Belakhlef, A., Ma, Y., Pillai, V., Chaly, T., Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects (2003) J Nucl Med, 44, pp. 961-966
Deterding, T.A., Votaw, J.R., Wang, C.K., Eshima, D., Eshima, L., Keil, R., Biodistribution and radiation dosimetry of the dopamine transporter ligand (2001) J Nucl Med, 42, pp. 376-381
Takano, A., Gulyas, B., Varrone, A., Karlsson, P., Schou, M., Airaksinen, A., Vandenhende, F., Halldin, C., Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 (2007) Eur J Nucl Med Mol Imaging, 48, p. 247
Guidance on medical exposures in medical and biomedical research (1998) Radiation Protection, 99. , European Commission
Beekhuis, H., Population radiation absorbed dose from nuclear medicine procedures in the Netherlands (1988) Health Phys, 54, pp. 287-291
Blakely, R. D., De Felice, L. J., Hartzell, H. C., Molecular physiology of norepinephrine and serotonin transporters (1994) J Exp Biol, 196, pp. 263-28
Bymaster, F. P., Katner, J. S., Nelson, D. L., Hemrick-Luecke, S. K., Threlkeld, P. G., Heiligenstein, J. H., Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder (2002) Neuropsychopharmacology, 27, pp. 699-711
Wrobel, M. C., Carey, J. E., Sherman, P. S., Kilbourn, M. R., Simplifying the dosimetry of carbon-11-labeled radiopharmaceuticals (1997) J Nucl Med, 38, pp. 654-660
Cloutier, R. J., Smith, S. A., Watson, E. E., Snyder, W. S., Warner, G. G., Dose to the fetus from radionuclides in the bladder (1973) Health Phys, 25, pp. 147-161
Stabin, M. G., Siegel, J. A., Physical models and dose factors for use in internal dose assessment (2003) Health Phys, 85, pp. 294-310
Stabin, M. G., Sparks, R. B., Crowe, E., OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine (2005) J Nucl Med, 46, pp. 1023-1027
Fowler, J. S., Ding, Y. S., Logan, J., MacGregor, R. R., Shea, C., Garza, V., Species differences in [11C] clorgyline binding in brain (2001) Nucl Med Biol, 28, pp. 779-785
Lu, J. Q., Ichise, M., Liow, J. S., Ghose, S., Vines, D., Innis, R. B., Biodistribution and radiation dosimetry of the serotonin transporter ligand 11C-DASB determined from human whole-body PET (2004) J Nucl Med, 45, pp. 1555-1559
Tipre, D. N., Lu, J. Q., Fujita, M., Ichise, M., Vines, D., Innis, R. B., Radiation dosimetry estimates for the PET serotonin transporter probe 11C-DASB determined from whole-body imaging in non-human primates (2004) Nucl Med Commun, 25, pp. 81-86
Stabin, M. G., MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine (1996) J Nucl Med, 37, pp. 538-546
Ding, Y. S., Lin, K. S., Garza, V., Carter, P., Alexoff, D., Logan, J., Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs (2003) Synapse, 50, pp. 345-352
Mejia, A. A., Nakamura, T., Masatoshi, I., Hatazawa, J., Masaki, M., Watanuki, S., Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies (1991) J Nucl Med, 32, pp. 699-706
Deterding, T. A., Votaw, J. R., Wang, C. K., Eshima, D., Eshima, L., Keil, R., Biodistribution and radiation dosimetry of the dopamine transporter ligand (2001) J Nucl Med, 42, pp. 376-381
Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S, S)-[18F]FMeNER-D2: A human whole-body PET study
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(206 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(284 visite) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 DettagliEsporta in BibTeXEsporta in EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(422 visite) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 DettagliEsporta in BibTeXEsporta in EndNote
Malvindi MA, Greco A, Conversano F, Figuerola A, Corti M, Bonora M, Lascialfari A, Doumari HA, Moscardini M, Cingolani R, Gigli G, Casciaro S, Pellegrino T, Ragusa A * MR Contrast Agents(230 visite) Small Animal Imaging, 2011 Jul 8; 21(13): 2548-2555. Impact Factor:1.784 DettagliEsporta in BibTeXEsporta in EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(409 visite) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 DettagliEsporta in BibTeXEsporta in EndNote